ArticleInflammopharmacology2026
Agomelatine for Sjögren's syndrome: a study on its therapeutic effects and mechanisms.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSjogren's Syndrome (SS) is an autoimmune disease characterized mainly by xerostomia (dry mouth), xerophthalmia (dry eyes) and damage of immune system. Recent studies have found that SS patients frequently experience neuropsychiatric symptoms such as depression and fatigue, suggesting potential underlying mechanisms involving complex immune-neural interactions. However, current therapeutic strategies targeting this immune-neuropsychiatric axis remain limited. Agomelatine (AGO), a novel antidepressant classified as a melatonin (MLT) receptor agonist and a 5-HT2C receptor antagonist, has yet to be fully investigated for its immunomodulatory potential and therapeutic application in SS.
objectivesThis study explores the immune-neuropsychiatric interaction in SS using Non-Obese Diabetic (NOD) mice, and investigates the therapeutic potential of AGO, highlighting its anti-inflammatory and immunomodulatory effects.
methodsNOD mice were divided into blank control, hydroxychloroquine (HCQ, a basic immune regulatory drug), MLT, and AGO groups; ICR mice served as healthy controls. All received intraperitoneal injections for 4 weeks. Behavioral tests (open field and tail suspension) were conducted. Flow cytometric analysis was performed to systematically evaluate splenic T cell and B cell subsets. The results showed that only the proportions of T helper 1 (Th1) and T helper 17 (Th17) cells exhibited significant differences, whereas no obvious changes were observed in B cells or regulatory T cells (Tregs).Salivary gland tissues were assessed by Hematoxylin-Eosin (HE) staining for inflammation and damage, and by immunofluorescence for Th1-epithelial cell co-localization.
resultsAGO-treated mice showed significantly shorter immobility time in the tail suspension test versus untreated NOD controls, indicating reduced despair. AGO intervention also reduced splenic Th1 and Th17 cell proportions, alleviated salivary gland lymphocyte infiltration, and decreased Th1-epithelial cell co-localization, suggesting inhibition of Th1 cell migration to target tissues.
conclusionAGO significantly improved behavioral performance, reduced the proportion of Th1 cells in the spleen, and alleviated inflammatory infiltration in the salivary glands of NOD mice. These findings suggest that the drug may exert therapeutic effects by modulating immune responses and neurobehavioral functions, positioning it as a promising candidate for the treatment of SS.
Indexed as
Identifiers
42406252What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.